News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Sciele Pharma, Inc. (SCRX) Reports That FDA Extends PDUFA Date on New Sular Formulation to January 2, 2008



11/5/2007 11:06:45 AM

ATLANTA--(BUSINESS WIRE)--Sciele Pharma, Inc. (NASDAQ:SCRX) today announced that the U.S. Food & Drug Administration (FDA) has extended to January 2, 2008, the Prescription Drug User Fee Act (PDUFA) date on Sciele's new Sular formulation. The new Sular formulation utilizes SkyePharma's (LSE:SKP) patented Geomatrix ® technology, which is designed to provide a lower dose of Sular for each of its current doses.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES